Study of JMT101 with Irinotecan for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, JMT101, combined with irinotecan for people with metastatic colorectal cancer that has continued to grow after two prior treatments. It is for those with specific genetic types (RAS and BRAF wild-type) and aims to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old.
- Have metastatic colorectal cancer that has gotten worse after two or more prior treatments.
- Your cancer must have specific genetic markers (RAS and BRAF wild-type) and not be MSI-H or dMMR.
- Be well enough to carry out daily activities (ECOG score 0 or 1).
- Have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted therapy (JMT101) with chemotherapy for a type of lung cancer called squamous cell non-small cell lung cancer that has a specific marker (EGFR). It is for patients whose cancer has gotten worse after prior immunotherapy and chemotherapy.
This trial tests a new drug called JMT108 for people with advanced solid tumors that haven't responded to standard treatments. It aims to find out if the drug is safe and how well it works against cancer.
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
This trial tests a combination of radiation therapy, an immunotherapy drug (QL1706), and two targeted drugs (TAS-102 and bevacizumab) for people with advanced colorectal cancer that has spread and is not removable by surgery. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
Hear when a new Metastatic Colorectal Cancer (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.